Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa

J Clin Oncol. 2013 Nov 20;31(33):4271. doi: 10.1200/JCO.2013.51.0289. Epub 2013 Oct 14.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / metabolism*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Erb-b2 Receptor Tyrosine Kinases / metabolism*
  • Female
  • Humans
  • Paclitaxel / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Quinazolines / therapeutic use*

Substances

  • Biomarkers, Tumor
  • Paclitaxel
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Quinazolines
  • Erb-b2 Receptor Tyrosine Kinases